prednisone has been researched along with abiraterone acetate in 203 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 124 (61.08) | 24.3611 |
| 2020's | 79 (38.92) | 2.80 |
| Authors | Studies |
|---|---|
| Acharya, M; Chi, KN; Gonzalez, M; Jiao, JJ; Kheoh, T; Molina, A; Pankras, C; Pili, R; Shore, ND; Tolcher, AW; Tran, N; Trinh, A | 1 |
| Printz, C | 1 |
| Acharya, M; Bernard, A; Chi, KN; Jiao, J; Kaiser, B; Kollmannsberger, CK; Lee, P; Molina, A; Pankras, C; Papadopoulos, KP; Patnaik, A; Rosen, PJ; Tolcher, A; Tran, N | 1 |
| Basch, E; Chi, KN; de Bono, JS; Efstathiou, E; Fizazi, K; Gagnon, DD; Goodman, OB; Hao, Y; Haqq, CM; Jones, RJ; Kheoh, TS; Liu, CS; Logothetis, CJ; Mainwaring, PN; Molina, A; North, SA; Rothman, M; Scher, HI; Sternberg, CN | 1 |
| Antonarakis, ES; Schweizer, MT | 1 |
| Cleeland, C; de Bono, JS; Fizazi, K; Gagnon, DD; Hao, Y; Haqq, CM; Kheoh, T; Mainwaring, P; Molina, A; North, S; Rothman, M; Scher, HI; Sternberg, CN | 1 |
| Basch, E; Carles, J; de Bono, JS; de Souza, P; Efstathiou, E; Fizazi, K; Flaig, TW; George, DJ; Gerritsen, WR; Griffin, T; Higano, CS; Kheoh, T; Logothetis, CJ; Mainwaring, P; Molina, A; Mukherjee, SD; Mulders, PF; Ng, S; Pantuck, A; Park, Y; Piulats, JM; Rathkopf, DE; Ryan, CJ; Saad, F; Scher, HI; Schrijvers, D; Small, EJ; Smith, MR; Suttmann, H; Taplin, ME; Van Poppel, H; Winquist, E; Yu, EY | 1 |
| Saylor, PJ | 1 |
| de Bono, JS; Grant, RP; Haqq, CM; Kheoh, T; Li, J; Molina, A; Ryan, CJ; Scher, HI; Small, EJ | 1 |
| Berruti, A; Caffo, O; Chierichetti, F; Galligioni, E; Maines, F; Palermo, A; Veccia, A | 1 |
| de Braud, F; Grassi, P; Procopio, G; Salvioni, R; Testa, I; Torri, V; Valdagni, R; Verzoni, E | 1 |
| Autio, K; Basch, E; Cleeland, C; Fizazi, K; Griffin, T; Hao, Y; Kheoh, T; Li, S; Logothetis, CJ; Mainwaring, PN; Meyers, ML; Molina, A; Mulders, P; Rathkopf, D; Ryan, CJ; Shore, N; Smith, MR | 1 |
| de Bono, JS; Fizazi, K; Flaig, TW; Goodman, OB; Kheoh, T; Li, J; Molina, A; Mulders, PF; Scher, HI; Suttmann, H | 1 |
| Chi, KN; Fizazi, K; Haqq, CM; Higano, CS; Kheoh, T; Li, J; Marberger, M; Molina, A; Mulders, PF; Saad, F | 1 |
| Aziz, R; Ghosh, D; Ibrahim, A; Justice, R; Kluetz, PG; Maher, VE; Mehrotra, N; Ning, YM; Palmby, T; Pazdur, R; Pfuma, E; Sridhara, R; Tang, S; Tilley, A; Zhang, L; Zirkelbach, JF | 1 |
| Hoy, SM | 1 |
| Atenafu, EG; Attard, G; de Bono, JS; Joshua, AM; Keizman, D; Knox, JJ; Leibowitz-Amit, R; Omlin, A; Pezaro, C; Seah, JA; Sridhar, SS; Tannock, IF; Templeton, AJ; Vera-Badillo, F | 1 |
| Chandler, DW; Haqq, CM; Kheoh, T; Molina, A; Peng, W; Ryan, CJ; Scher, HI; Welkowsky, E | 1 |
| Beer, TM; Carles, J; de Bono, JS; de Souza, P; Efstathiou, E; Fizazi, K; Flaig, TW; Fradet, Y; Griffin, TW; Hainsworth, JD; Higano, CS; Kheoh, T; Logothetis, CJ; Mainwaring, P; Molina, A; Mulders, PF; North, S; Park, YC; Rathkopf, DE; Ryan, CJ; Saad, F; Scher, HI; Shore, ND; Small, EJ; Smith, MR; Taplin, ME; Todd, MB; Van Poppel, H; Yu, EY; Yu, MK | 1 |
| Ellis, L; Grittner, AM; Kozma, C; Lafeuille, MH; Lefebvre, P; McKenzie, RS; Slaton, T | 1 |
| Boissier, E; Loriot, Y; Massard, C; Vignot, S | 1 |
| Ma, H; Wan, B; Wang, JY; Wu, PJ; Zhu, G | 1 |
| Basch, E; Bennett, CL; Carducci, M; Chen, RC; Dusetzina, SB; Frame, JN; Garrels, K; Hotte, S; Kattan, MW; Loblaw, DA; Oliver, TK; Raghavan, D; Rumble, RB; Saad, F; Taplin, ME; Virgo, KS; Walker-Dilks, C; Williams, J; Winquist, E; Wootton, T | 1 |
| Attard, G; de Bono, JS; Fizazi, K; Griffin, TW; Joshua, AM; Kheoh, T; Li, W; Logothetis, CJ; Molina, A; Mukherjee, SD; Rathkopf, DE; Ricci, DS; Ryan, CJ; Scher, HI; Schrijvers, D; van den Eertwegh, AJ; Zelinsky, K | 1 |
| Burzykowski, T; de Bono, JS; de Souza, P; Fizazi, K; Griffin, TW; Higano, CS; Kantoff, PW; Kheoh, T; Larson, SM; Li, J; Logothetis, CJ; Matheny, SL; Molina, A; Morris, MJ; Naini, V; Ryan, CJ; Scher, HI; Small, EJ | 1 |
| Armstrong, AJ; Chin, B; Dhawan, MS; George, DJ; Harrison, MR; Healy, P; Oldan, J; Zhang, T | 1 |
| Chang, N; DeVries, T; Fong, L; Gardner, TA; GuhaThakurta, D; Karsh, LI; Lance, RS; McCoy, C; Redfern, CH; Sheikh, NA; Shore, ND; Small, EJ | 1 |
| De Rubertis, G; Fiaschi, AI; Francini, E; Laera, L; Miano, ST; Petrioli, R; Roviello, G | 1 |
| Beer, TM; de Bono, JS; De Porre, P; de Souza, P; Fizazi, K; Fradet, Y; Griffin, TA; Hainsworth, JD; Kheoh, T; Logothetis, CJ; Londhe, A; Mainwaring, P; Molina, A; Mulders, PF; North, S; Rathkopf, DE; Ryan, CJ; Saad, F; Scher, HI; Shore, N; Small, EJ; Smith, MR; Van Poppel, H | 1 |
| Beuzeboc, P; Massard, C | 1 |
| Barkin, J | 1 |
| Acharya, M; Bernard, A; Chi, KN; Chien, C; Gonzalez, M; Griffin, TW; Jiao, J; Kheoh, T; Kollmannsberger, C; North, S; Pankras, C; Peng, L; Spratlin, J; Stieltjes, H; Tran, NP; Yu, MK | 1 |
| Carles, J; Griffin, TW; Kheoh, T; Li, J; Molina, A; Mulders, PF; Rathkopf, DE; Ryan, CJ; Smith, MR; Van Poppel, H | 1 |
| Carprieaux, M; Rappe, B; Schallier, D; Vandenbroucke, F | 1 |
| Bellmunt, J; Davis, ID; de Bono, JS; De Porre, P; Fizazi, K; Griffin, TW; Kheoh, T; Molina, A; Mulders, PF; Oudard, S; Protheroe, A; Rathkopf, DE; Ryan, CJ; Saad, F; Scher, HI; Schrijvers, D; Small, EJ; Smith, MR; Taplin, ME; Yu, MK | 1 |
| de Bono, JS; Fizazi, K; Flaig, TW; Griffin, TW; Kheoh, T; Li, J; Molina, A; Ohlmann, CH; Rathkopf, DE; Ryan, CJ; Scher, HI; Stöckle, M; Todd, MB | 1 |
| Azad, AA; Bellmunt, J; Chi, KN; de Bono, JS; Eigl, BJ; Fizazi, K; Heng, DY; Joshua, AM; Kantoff, PW; Kheoh, T; Li, J; Molina, A; Rathkopf, DE; Ryan, CJ; Scher, HI; Vogelzang, NJ | 1 |
| Bruce, J; De Porre, P; Gonzalez, MD; Kheoh, T; Lim, EA; Maul, S; Nanus, DM; Peng, W; Petrylak, DP; Posadas, EM; Smit, JW; Tagawa, ST; Tran, N | 1 |
| Chen, Z; De Porre, P; Du, C; Feng, Y; Huang, Y; Jin, J; Li, C; Lin, G; Liu, W; Shan, Y; Sun, Y; Sun, Z; Xie, L; Ye, D; Ye, ZQ; Zou, Q | 1 |
| Charnas, R; Chi, KN; de Bono, JS; De Porre, P; Fizazi, K; Gomella, LG; Londhe, A; McGowan, T; Miller, K; Montgomery, B; Pelhivanov, N; Rathkopf, DE; Ryan, CJ; Scher, HI; Shore, ND; Todd, MB | 1 |
| Aggarwal, R | 1 |
| Ellis, LA; Lefebvre, P; Pilon, D; Queener, M | 1 |
| Abadie-Lacourtoisie, S; Bidard, FC; Bonnefoi, H; Cottu, P; Coussy, F; Dalenc, F; Dauba, J; Del Piano, F; Desmoulins, I; Gonçalves, A; Grellety, T; Grenier, J; L'Haridon, T; MacGrogan, G; Madranges, N; Mailliez, A; Mousseau, M; Orsini, C; Proudhon, C; Pulido, M; Saghatchian, M; Tredan, O; You, B | 1 |
| Bottini, A; Generali, D; Roviello, G | 1 |
| De Porre, P; Fizazi, K; Londhe, A; McGowan, T; Ryan, CJ | 1 |
| De Porre, P; Griffin, TW; Nandy, P; Park, YC; Poggesi, I; Ryan, CJ; Saad, F; Smith, MR; Stuyckens, K; Vermeulen, A; Xu, XS; Yu, MK | 1 |
| de Bono, JS; De Porre, P; Fizazi, K; Flaig, TW; Kheoh, T; Li, J; Mulders, PFA; Rathkopf, DE; Ryan, CJ; Saad, F; Shore, ND; Small, EJ; Smith, MR; Todd, MB | 1 |
| Binder, M; Hillman, DW; Kohli, M; Kohli, R; Kohli, T; Lee, A; Zhang, BY | 1 |
| Generali, D; Petrioli, R; Roviello, G | 1 |
| Armstrong, N; Deshpande, S; Duffy, S; Joore, MA; Kleijnen, J; Ramaekers, BLT; Riemsma, R; Severens, JL; Tomini, F; van Asselt, T | 2 |
| Balk, M; Barlev, A; Brown, B; Bui, CN; Flanders, S; Guo, J; Massoudi, M; Pandya, BJ; Song, Y; Wu, EQ; Yang, H | 1 |
| Bulone, L; Galsky, MD; Gimpel-Tetra, K; Kemeny, M; Liaw, B; Oh, WK; Sfakianos, J; Shahin, M; Tsao, CK | 1 |
| de Wit, R; van Soest, RJ | 1 |
| Araujo, JC; Efstathiou, E; Gyftaki, R; Li-Ning-Tapia, EM; Logothetis, CJ; Lu, JF; Maity, SN; Ramachandran, S; Titus, MA; Wu, G | 1 |
| de Bono, J | 1 |
| Agarwal, N; Alex, A; Bailey, E; Batten, J; Boucher, K; Gaston, D; Gill, D; Gupta, S; Hahn, A; Stenehjem, D | 1 |
| Clausse, M; D'Hondt, L; Demey, W; Everaert, E; Filleul, B; Gil, T; Goeminne, JC; Lumen, N; Machiels, JP; Mebis, J; Pelgrims, G; Rasschaert, M; Rottey, S; Schallier, D; Schatteman, P; Schrijvers, D; Van Aelst, F; Van Erps, J; Van Haverbeke, J; Van Hende, F; Van Praet, C; Verheezen, J; Vermeij, J; Werbrouck, P; Wynendaele, W | 1 |
| de Bono, JS; De Porre, P; Fizazi, K; Kheoh, T; Li, J; Mulders, PFA; Rathkopf, DE; Ryan, CJ; Saad, F; Shore, ND; Small, EJ; Smith, MR; Todd, MB; Yu, MK | 1 |
| Bracarda, S; Crucitta, S; Danesi, R; De Souza, P; Del Re, M; Derosa, L; Fogli, S; Massari, F; Santini, D | 1 |
| Agarwal, N; Deshpande, HA; Flaig, TW; Hussain, MHA; Mitsiades, N; Plets, M; Thompson, IM; Vaishampayan, UN | 1 |
| Girod, I; Hall, F; Lee, J; Proskorovsky, I; Reifsnider, O; Sorensen, S | 1 |
| Breaker, K; Flaig, TW; Gao, D; Kessler, ER; Lam, ET; Wacker, M; Wold, M | 1 |
| Balk, SP; Blair, IA; Bubley, G; Mesaros, C; Montgomery, B; Mostaghel, EA; Penning, TM; Tamae, D; Taplin, ME; Xie, W; Zang, T; Zhang, Z | 1 |
| Black, PC; Struss, WJ | 1 |
| Scott, LJ | 1 |
| Baron, B; Chowdhury, S; de Bono, JS; Elliott, T; Feyerabend, S; Fizazi, K; Grande, E; Hirmand, M; Melhem-Bertrandt, A; Werbrouck, P | 1 |
| Brookman-May, SD; Carles, J; Diels, J; Gschwend, JE; Miller, K; Van Poppel, H | 1 |
| Fujii, Y; Saito, K | 1 |
| Atwell, TD; Barman, P; Bhargava, V; Bryce, AH; Carlson, RE; Costello, BA; Dehm, SM; Eckloff, BW; Eiken, P; Ellingson, M; Gormley, M; Hart, SN; Hillman, DW; Ho, T; Huang, H; Jen, J; Jimenez, R; Kalari, KR; Kohli, M; Li, Y; McMenomy, BP; Ou, F; Pitot, HC; Qin, R; Qin, S; Quevedo, F; Sicotte, H; Tan, W; Vedell, PT; Wang, L; Weinshilboum, RM; Wieben, ED; Xie, F; Ye, Z; Yin, P | 1 |
| Culine, S | 1 |
| Bosch, B; Chapas-Reed, J; Dreicer, R; Given, R; Higano, CS; Levin, R; Nemeth, P; Stein, CA | 1 |
| Harrelson, SS; Mariados, NF; Mehlhaff, BA; Nordquist, LT; Shore, ND; Steere, KJ; Tutrone, RF | 1 |
| Cella, D; Ho, KF; Johnson, K; Li, T; Molina, A; Shore, ND; Traina, S | 1 |
| Attard, G; Linch, M | 1 |
| Penson, DF | 1 |
| Chi, KN; Damião, R; De Porre, P; Facchini, G; Fizazi, K; Jia, B; Keam, B; Li, T; Martin, J; Matsubara, N; McQuarrie, K; Protheroe, A; Rodríguez-Antolín, A; Suttman, H; Todd, MB; Ye, Z | 1 |
| Fenner, A | 1 |
| Elkon, JM; Lin, J; Millado, KF; Millett, RL | 1 |
| Baciarello, G; Fizazi, K; Hamilou, Z | 1 |
| Gourd, E | 1 |
| de Reijke, TM; Poorthuis, MHF; van Moorselaar, RJA; Vernooij, RWM | 1 |
| Al-Salama, ZT | 1 |
| Crawford, ED; Francis, PSJ; Kantoff, PW; Londhe, A; McGowan, T; Phillips, J; Ryan, CJ; Shore, ND; Taplin, ME; Underwood, W | 1 |
| Agarwal, N; Cannon-Albright, L; Farnham, J; Gill, DM; Hahn, AW; Nussenzveig, RH; Poole, A | 1 |
| Campins, L; Font, A; Lianes, P; Marin, S; Miarons, M; Querol, R | 1 |
| Saad, F | 2 |
| Winquist, E | 1 |
| Burdett, S; Carpenter, JR; Clarke, NW; Fisher, DJ; Fizazi, K; Gravis, G; James, ND; Mason, MD; Parmar, MKB; Rydzewska, LH; Spears, MR; Sweeney, CJ; Sydes, MR; Tierney, JF; Vale, CL; White, IR | 1 |
| Abogunrin, S; De Porre, P; Diels, J; Feyerabend, S; Fizazi, K; Ito, T; Koufopoulou, M; Li, T; Roiz, J; Saad, F; Van Sanden, S | 1 |
| Barata, PC; Edwin, NC; Emamekhoo, H; Garcia, JA; Grivas, P; Woo, KM | 1 |
| Scher, HI; Teo, MY | 1 |
| Aieta, M; Bonetta, A; Conca, R; Petrioli, R; Rodriquenz, MG; Roviello, G | 1 |
| Enjo, K; Fizazi, K; Fukasawa, S; Kawaguchi, K; Matsubara, N; Noguchi, H; Suzuki, H; Todd, M; Tran, N | 1 |
| Artenie, C; Dearden, L; Gater, A; Grant, L; Jackson, C; Mills, A; Shalet, N | 1 |
| Chi, C; Dong, B; Fan, L; Gong, Y; Huang, Y; Pan, J; Sha, J; Shangguan, X; Wang, Y; Xue, W; Zhou, L | 1 |
| Chi, KN; Franco-Villalobos, C; Li, T; Proskorovsky, I; Sorensen, SV; Sulur, G; Tran, N | 1 |
| Agarwal, N; Cannon-Albright, LA; Farnham, JM; Gill, DM; Hahn, AW; Maughan, BL; Nussenzveig, RH; Poole, A; Stephenson, RA; Wilson, S | 1 |
| Chi, C; Dong, B; Fan, L; Gong, Y; Ma, X; Pan, J; Wang, R; Xue, W; Yang, Y; Zheng, H; Zhu, Y | 1 |
| Alvarez, LG; Antoni, L; Bera, G; Birtle, A; Boegemann, M; Dopchie, C; Dourthe, LM; Elliott, T; Everaert, E; Hatzinger, M; Hercher, D; Hilgers, W; Khaksar, S; Lukac, M; Matus, G; Pissart, G; Robinson, P | 1 |
| Aksoy, S; Besen, AA; Guler, OC; Kose, F; Mertsoylu, H; Muallaoglu, S; Onal, C; Oymak, E; Ozyigit, G; Sedef, AM; Sumbul, AT; Yildirim, BA | 1 |
| Berruti, A; Dalla Volta, A; Formenti, AM | 1 |
| Boegemann, M; Heidenreich, A; Higano, C; Kakehi, Y; Karyakin, O; Kimura, G; Krissel, H; Matsubara, N; Matveev, V; Miller, K; Nahas, WC; Ng, QS; Nolè, F; Parker, C; Piulats, JM; Rosenbaum, E; Saad, F; Shen, J; Smith, M; Teufel, M; Tombal, B; Wagner, V; Zhang, A; Zucca, LE | 1 |
| Spratt, DE | 1 |
| Duarte, C; Jimeno, A; Kessler, ER | 1 |
| Beijnen, JH; Rosing, H; van Nuland, M; van Rossum, HH; Venekamp, N; Wouters, WME | 1 |
| Aronson, WJ; Bennett, CJ; Garraway, IP; Gin, GE; Huiza, C; Inouye, WS; Jafari, L; Jordan, ML; Kalpage, N; Kishan, AU; Lee, SP; Lewis, M; Nickols, NG; Parikh, NR; Patel, JS; Pitcher, S; Reiter, RE; Rettig, MB; Sadeghi, A; Sanati, H; Thein, M; Tsai, S | 1 |
| Cursano, MC; De Giorgi, U; Iuliani, M; Paganelli, G; Santini, D | 1 |
| Hindié, E; Morgat, C | 1 |
| Antonarakis, ES; Carducci, MA; Denmeade, SR; Qiu, F; Teply, BA | 1 |
| Arasaratnam, M; Bhatnagar, A; Crumbaker, M; Gurney, H; McKay, MJ; Molloy, MP | 1 |
| Barrios, C; Carrera Souza, V; Cronemberger, EH; Dos Santos Martins, SP; Fay, A; Herchenhorn, D; Maluf, FC; Mavignier Carcano, F; Nunes Filho, PRS; Peixoto, F; Queiroz Muniz, D; Santos, T; Schutz, F; Smaletz, O; Werutsky, G; Zaffaroni, F | 1 |
| Davis, JW; Efstathiou, E; Gormley, M; Hoang, A; Kheoh, T; Li, W; Logothetis, CJ; McMullin, RP; Molina, A; Peng, W; Pisters, L; Ricci, D; Titus, M; Tran, N; Troncoso, P; Wen, S; Zurita, AJ | 1 |
| Castellan, P; Castellucci, R; Cindolo, L; De Nunzio, C; Marchioni, M; Primiceri, G; Schips, L; Tema, G | 1 |
| van der Poel, H | 1 |
| Cuevas Sanz, JM; García García-Porrero, Á; González-Del-Alba, A; Méndez-Vidal, MJ; Muñoz Del Toro, JR; Pinto, A; Puente, J; Rodríguez, Á; Sala-Gonzalez, N; Useros Rodríguez, E; Vázquez, S | 1 |
| Fradet, V; Loubersac, T; Nguile-Makao, M; Pouliot, F; Toren, P | 1 |
| George, DJ | 1 |
| Gervasi, L; McGowan, T; Mehlhaff, B; Pei, H; Phillips, J; Saltzstein, D; Shore, ND; Sieber, P; Wong, YN | 1 |
| Fujii, Y; Hinotsu, S; Izumi, K; Kimura, G; Mizokami, A | 1 |
| Figg, WD; Knechel, MA; Schmidt, KT | 1 |
| Beal-Ardisson, D; Birtle, A; Dourthe, LM; Lagneau, E; Lefresne, F; Lukac, M; Pintus, E; Pissart, G; Ploussard, G; Poulsen, MH; Reid, A; Thiery-Vuillemin, A; Trepiakas, R; Van Sanden, S | 1 |
| Corona, SP; D'Angelo, A; Roviello, G; Sobhani, N | 1 |
| Chan, J; Chow, M; Chua, M; Fong, YC; Kanesvaran, R; Lee, LS; Lim, HC; Loh, KY; Ng, QS; Rajasekaran, T; Toh, CK; Wong, A; Wong, SW; Yap, SY | 1 |
| Annala, M; Attwell, A; Azad, AA; Chi, KN; Eigl, BJ; Ellard, SL; Finch, DL; Gleave, ME; Keith, B; Khalaf, DJ; Kollmannsberger, CK; Le, L; Noonan, K; Oja, C; Sunderland, K; Taavitsainen, S; Vergidis, J; Wadhwa, D; Wyatt, AW; Zulfiqar, M | 1 |
| De Porre, P; Diels, J; Feyerabend, S; Fizazi, K; Ito, T; Perualila, NJ; Saad, F; Van Sanden, S | 1 |
| Sidaway, P | 1 |
| Tombal, B | 1 |
| Hosono, M; Kakehi, Y; Kikukawa, H; Kimura, G; Kinuya, S; Krissel, H; Matsubara, N; Mizokami, A; Nagamori, S; Nakamura, M; Siegel, J; Uemura, H | 1 |
| Alekseev, BY; Chi, KN; De Porre, P; Fein, L; Feyerabend, S; Fizazi, K; Li, S; Matsubara, N; Mundle, S; Özgüroğlu, M; Protheroe, A; Rodriguez-Antolin, A; Sulur, G; Tran, N | 1 |
| Alyamani, M; Auchus, RJ; O'Day, P; Sharifi, N; Wright, C | 1 |
| Baser, O; George, DJ; Huang, A; Lechpammer, S; Mardekian, J; Ramaswamy, K; Sandin, R; Schultz, NM; Wang, L | 1 |
| Albiges, L; Alexandre, J; Baciarello, G; Carton, E; Colomba, E; Culine, S; Fizazi, K; Huillard, O; Lavaud, P; Loriot, Y; Marret, G; Massard, C | 1 |
| Fizazi, K; Fukasawa, S; Hashine, K; Kitani, S; Matsubara, N; Mundle, S; Ohtake, N; Shibayama, K; Shin, T; Suzuki, H; Tran, N | 1 |
| Du, M; Huang, CC; Kilari, D; Kohli, M; Tan, W; Tian, Y; Wang, L | 1 |
| Baurecht, W; Belz, H; Bögemann, M; Feyerabend, S; Kruetzfeldt, K; Merseburger, AS; Rüssel, C; Spiegelhalder, P; Tran, N | 1 |
| Hess, BA | 1 |
| Abrams, C; Attard, G; Chi, KN; Chien, C; de Jonge, MJA; de Wit, R; Friedlander, TW; Hellemans, P; Jiao, JJ; Posadas, EM; Saad, F; Yu, MK | 1 |
| Abou Chakra, M; Dellis, A; Moussa, M; Papatsoris, A; Sryropoulou, D | 1 |
| Eterović, D; Omrčen, T; Vrdoljak, E | 1 |
| Miller, K | 1 |
| Manceau, C; Mourey, L; Ploussard, G; Pouessel, D | 1 |
| Aparicio, A; Araujo, JC; Boukovala, M; Corn, PG; Efstathiou, E; Hoang, A; Kim, J; Logothetis, CJ; Pagliaro, L; Spetsieris, N; Subudhi, SK; Tannir, NM; Troncoso, P; Tsikkinis, A; Tu, SM; Wang, J; Wang, X; Weldon, JA; Wen, S; Zurita, AJ | 1 |
| Fan, YC; Fang, WY; Shih, HJ; Wang, PF | 1 |
| De Porre, P; Londhe, A; Morris, MJ; Qi, K; Rao, A; Ryan, C; Scher, HI; Yu, MK | 1 |
| Anand, M; Armstrong, AJ; Berry, WR; Corn, PG; George, DJ; Halabi, S; Harrison, MR; Healy, P; Hoffman, KE; Koontz, BF; Lee, WR; Zhang, T | 1 |
| Asensio, I; Casado, MA; Cassinello, J; Domínguez-Lubillo, T; Gómez-Barrera, M; Hernando, T; Moreno, P; Parra, R | 1 |
| Bhak, RH; Freedland, SJ; Lefebvre, P; Li, S; Narkhede, S; Pilon, D; Young-Xu, Y | 1 |
| Benoist, GE; Boerrigter, E; de Mol, P; Groen, L; Mehra, N; Oving, IM; Schalken, JA; Smilde, TJ; Smit, F; Somford, DM; van Erp, NP; van Hooij, O; van Oort, IM; Verhaegh, GW | 1 |
| Bubley, GJ; Calagua, C; Chang, PK; Chang, SL; Choudhury, AD; Einstein, DJ; Fennessy, FM; Kibel, AS; Kilbridge, K; Laudone, VP; Lis, R; McKay, RR; Parsons, JK; Pomerantz, MM; Preston, MA; Rathkopf, D; Taplin, ME; Trinh, QD; Wagner, AA; Xie, W; Ye, H; Zhang, Z | 1 |
| Albany, C; Dawson, NA; Higano, CS; Mehlhaff, BA; Nordquist, LT; Patel, KR; Petrylak, DP; Quinn, DI; Sartor, O; Siegel, J; Trandafir, L; Vaishampayan, UN; Wagner, VJ | 1 |
| Birtle, A; Bjartell, A; Chowdhury, S; Costa, L; Feyerabend, S; Gomez-Veiga, F; Kalinka, E; Kramer, G; Lefresne, F; Lukac, M; Lumen, N; Maroto, P; Matveev, V; Paiss, T; Spaëth, D; Wapenaar, R | 1 |
| Anand, M; Armstrong, AJ; Bearden, J; Berry, W; Bitting, RL; Das, D; Fleming, MT; Freedman, JA; George, DJ; Goodman, M; Halabi, S; Harrison, MR; Healy, P; Heath, EI; Hyslop, T; Kephart, J; Kittles, RA; LaCroix, BL; McNamara, M; Milowsky, MI; Owzar, K; Patierno, BM; Patierno, SR; Rasmussen, J; Riggan, C; Sartor, AO; Shobe, K; Sibley, AB; Sonpavde, GP; Wilder, R; Winters, C; Zhang, D; Zhang, T | 1 |
| Crehange, G; Geoffrois, L; Gravis, G; Hennequin, C; Kleinclauss, F; Limat, S; Morgans, AK; Nerich, V; Oudard, S; Pelloux-Prayer, R; Schiele, P; Thiery-Vuillemin, A | 1 |
| Attard, G; Brown, LC; Clarke, NW; James, ND; Parmar, MKB | 1 |
| Bamias, A; Carles, J; Castellano, D; de Bono, J; de Wit, R; Eymard, JC; Feyerabend, S; Fizazi, K; Geffriaud-Ricouard, C; Helissey, C; Iacovelli, R; Kramer, G; Melichar, B; Ozatilgan, A; Poole, EM; Sternberg, CN; Sverrisdóttir, Á; Theodore, C; Tombal, B; Wülfing, C | 1 |
| Gallego, MC; Jimenez Romero, ME; Navarro Serrato, JC; Sanchez Hurtado, MA; Santotoribio, JD | 1 |
| Alimohamed, NS; Bengala, C; Bryce, AH; Cigliola, A; Crivelli, F; Francini, E; Francini, G; Garcia-Foncillas, J; Gonzalez-Velez, M; Harshman, LC; Heng, DYC; Higano, CS; Lee-Ying, R; Montagnani, F; Moreno-Candilejo, I; Nuzzo, PV; Petrioli, R; Rosellini, P; Rubio-Perez, J; Shaw, GK; Sweeney, CJ; Zhang, L | 1 |
| Chen, D; He, L; Jiang, L; Li, Y; Ni, Y; Shi, Y; Wang, J; Wang, Y; Wu, Z; Yang, Z; Zeng, H; Zhang, Y; Zhao, D; Zhou, F | 1 |
| Benoist, GE; Boerrigter, E; Donders, R; Mehra, N; Overbeek, JK; Ter Heine, R; van Erp, NP; van Oort, IM | 1 |
| Alafis, I; Aparicio, A; Araujo, J; Boukovala, M; Chapin, BF; Corn, P; Davis, J; Efstathiou, E; Logothetis, CJ; Papadopoulos, J; Pruitt, L; Spetsieris, N; Subudhi, SK; Tu, SM; Wang, J; Wang, X; Weldon, JA; Zurita, A | 1 |
| Attard, G; Bevans, KB; Brookman-May, S; De Porre, P; Efstathiou, E; Flaig, TW; Franke, F; Goodman, OB; Li, J; Li, S; McCarthy, SA; Mundle, SD; Oudard, S; Rathkopf, DE; Saad, F; Steuber, T; Suzuki, H; Thomas, S; Wu, D; Yeruva, K | 1 |
| Agarwal, N; Bruno, A; George, D; Guo, H; Higano, CS; Jiao, X; Miller, K; Saad, F; Sandström, P; Sartor, O; Shore, N; Sternberg, CN; Tombal, B; Verholen, F | 1 |
| Ameye, F; Baekelandt, F; Bamelis, B; De Roock, W; Denies, E; Duck, L; Filleul, B; Fransis, K; Ghysel, C; Hollebosch, S; Joniau, S; Lambert, E; Logghe, P; Lumen, N; Ost, D; Remondo, C; Sautois, B; Schatteman, P; Van Bruwaene, S; van Praet, C; van Wambeke, S; Vandenbroucke, F; Vergauwe, E; Wynendaele, W | 1 |
| Abdelsalam, M; Ataikiru, O; Avileli, M; Hynes, T | 1 |
| Baciarello, G; Chi, KN; Feyerabend, S; Fizazi, K; Hu, P; Leitz, G; Matsubara, N; Mundle, S; Özgüroğlu, M; Richarz, U | 1 |
| Mirjafary, Z; Mohammad Hossein Shirazi, S; Mokhtari, J | 1 |
| Baird, RD; Barry, ST; Choudhury, AD; Colebrook, S; Cook, N; de Bono, JS; de Bruin, EC; García-Carbacho, J; Hansen, AR; Hawkins, G; Heath, EI; Higano, CS; Klinowska, T; Linch, M; Maroj, B; Martin-Liberal, J; Moorthy, G; Mortimer, PG; Moschetta, M; Nikolaou, M; Quintela-Fandino, M; Rathkopf, DE; Sainsbury, L; Shapiro, GI; Siu, LL; Wisinski, KB | 1 |
| Appleman, LJ; Berry, WR; Bögemann, M; Conter, HJ; de Bono, JS; Emmenegger, U; Gravis, G; Gurney, H; Joshua, AM; Kolinsky, MP; Laguerre, B; Li, XT; Linch, M; Massard, C; Mourey, L; Piulats, JM; Poehlein, CH; Retz, M; Romano, E; Schloss, C; Sridhar, S; Yu, EY | 1 |
| Aglietta, M; Airoldi, M; Alitto, AR; Beccaglia, P; Bordonaro, R; Carella, C; Chiuri, VE; Cinieri, S; De Placido, S; Galli, L; Gasparro, D; Giordano, M; Guglielmini, PF; Livi, L; Ludovico, GM; Maisano, R; Nova, P; Procopio, G; Rossetti, S; Santini, D; Schips, L; Sciarra, A | 1 |
| Ali, A; Attard, G; Berthold, DR; Birtle, AJ; Brawley, CD; Brock, SJ; Buckner, ML; Chowdhury, S; Clarke, NW; Cook, A; Cross, WR; Das, P; de Bono, JS; Dearnaley, DP; Diaz-Montana, C; Ford, D; Gale, J; Gilbert, D; Gillessen, S; Gilson, C; Grant, W; Gray, EK; Hoskin, P; Hoyle, AP; James, ND; Jones, RJ; Khan, MM; Langley, RE; Malik, ZI; Manetta, C; Mason, MD; Matheson, DJ; McPhail, NJ; Millman, R; O'Sullivan, JM; Parikh, O; Parker, CC; Parmar, MKB; Perna, C; Pezaro, CJ; Protheroe, AS; Pugh, C; Ritchie, AWS; Robinson, AJ; Rudman, SM; Rush, H; Russell, JM; Sheehan, DJ; Srihari, NN; Sydes, MR; Syndikus, I; Tanguay, JS; Thomas, CW; Vengalil, S; Wagstaff, J; Wylie, JP | 1 |
| Feyerabend, S; Gleißner, J; Gschwend, J; Hellmis, E; Hübner, A; Jaehnig, P; Janssen, M; Jäschke, M; Junker, K; Klier, J; Krege, S; Marin, J; Mathers, M; Ohlmann, CH; Rexer, H; Rüssel, C; Scheffler, M; Stöckle, M; Suttmann, H; Telle, J; Zillmann, R | 1 |
| Cintra, MTG; Costa, AL; de Almeida, DCB; de Carvalho, FB; de Oliveira Faria, BL | 1 |
| Armstrong, AJ; Carles, J; Chi, KN; de Bono, J; De Porre, P; Fizazi, K; Gillessen, S; Hu, P; Jones, RJ; Joshua, AM; Logothetis, CJ; Rathkopf, D; Ryan, CJ; Saad, F; Scher, HI; Smith, MR; Sternberg, CN; Tran, N; Wilson, BE | 1 |
| Attard, G; Brawley, CD; Clarke, CS; Clarke, NW; Cross, W; Dearnaley, DP; Gabrio, A; Gillessen, S; Hunter, RM; Ingleby, FC; James, ND; Jones, RJ; Lester, JF; Malik, Z; Matheson, D; Millman, R; Parker, C; Parmar, MKB; Rush, HL; Russell, JM; Sydes, MR; Wylie, J | 1 |
| Bisbjerg, R; Faber, J; Fode, M; Kistorp, C; Klausen, TW; Lindberg, H; Palapattu, G; Sønksen, J; Ternov, KK; Østergren, PB | 1 |
| Cattrini, C; Di Maio, M; Gennari, A; Mennitto, A; Messina, C; Olmos, D | 1 |
| Ah-Thiane, L; Supiot, S | 1 |
| Bhargava, V; Bryce, AH; Carlson, RE; Dehm, SM; Gormley, M; Hillman, DW; Jimenez, RE; Kalari, KR; Kohli, M; Li, Y; Qin, S; Sicotte, H; Sinnwell, JP; Tan, W; Vedell, PT; Wang, L; Weinshilboum, RM | 1 |
| Armstrong, AJ; Lee, WR; Wang, EC | 1 |
| Basu, A; Carlson, JJ; Garrison, LP; Jiao, B; Nyame, YA | 1 |
| Koroki, Y; Taguri, M | 1 |
| Adra, N; Costin, D; Cullberg, M; Hauke, R; Mellado, B; Morris, T; Shah, S; Shore, N; Teruel, CF | 1 |
| Fiala, O; Finek, J; Hora, M; Hosek, P; Kolar, J; Korunkova, H; Sedlackova, H; Sorejs, O; Topolcan, O; Travnicek, I; Windrichova, J | 1 |
| Dai, JD; Shen, PF; Sun, GX; Wang, MH; Xu, NW; Zeng, H; Zeng, YH; Zhang, XM; Zhao, JG | 1 |
| Bracarda, S; Chen, G; Chi, KN; de Bono, J; Garcia, J; Harris, A; Hinton, H; Massard, C; Matsubara, N; Olmos, D; Sandhu, S; Sane, R; Schenkel, F; Sternberg, CN; Sweeney, C | 1 |
| Andrade, LMQS; De Giorgi, U; Fornarini, G; Fotia, G; Francini, E; Malgeri, A; Mestre, RP; Modesti, M; Nuzzo, PV; Patrikidou, A; Pederzoli, F; Pignata, S; Procopio, G; Rossetti, S; Russo, A; Saieva, C; Valenca Bueno, L; Zanardi, E | 1 |
| Azem, O; Camden, NB; Cueto-Marquez, AE; D'souza, LA; King, K; Kishan, AU; Malone, S; Morgan, SC; Roy, S; Saad, F; Spratt, DE; Sun, Y; Wallis, CJD; Zhou, YM | 1 |
| Attard, G; Chi, KN; Diorio, B; Efstathiou, E; Francis, P; Lee, JY; Lopez-Gitlitz, A; Mason, GE; Olmos, D; Pereira de Santana Gomes, AJ; Rathkopf, D; Roubaud, G; Saad, M; Sakalo, V; Sandhu, S; Small, EJ; Smith, MR; Wang, G; Wu, D; Zurawski, B | 1 |
| Chi, KN; Chiuri, VE; Daksh, M; De Porre, P; Fleshner, N; Hafron, J; Mason, GE; Maul, RS; McNeel, DG; Tutrone, RF; Van Bruwaene, S; Zhong, X | 1 |
| Antonarakis, ES; Armstrong, AJ; Beltran, H; Beumer, JH; Bobek, O; Bryce, AH; Goldkorn, A; Hahn, O; Halabi, S; Heller, G; Hillman, DW; Langevin, B; Lewis, LD; McGary, EC; Mehan, PT; Morris, MJ; Roth, BJ; Ryan, C; Schwartz, L; Small, EJ; Taplin, ME; Watt, C; Xiao, H | 1 |
| Choueiri, TK; Gillessen, S; McKay, RR; Ürün, Y; Yekedüz, E | 1 |
| Bjartell, A; Sjöström, M | 1 |
| Barthélémy, P; Bischoff, H | 1 |
| Hall, ME; Klaassen, Z; Laviana, AA; Luckenbaugh, AN; Magee, DE; Padgett, WJ; Satkunasivam, R; Schaffer, K; Wallis, CJD | 1 |
| Le, K; Li, G; Li, Y; Liu, M; Xing, N; Yan, J | 1 |
| Attard, G; Castro, E; Chi, KN; Del Corral, A; Dibaj, S; Diorio, B; Efstathiou, E; Francis, P; Gurney, H; Jung, W; Kim, W; Mason, GE; Olmos, D; Pereira de Santana Gomes, AJ; Rathkopf, DE; Roubaud, G; Saad, M; Sandhu, S; Small, EJ; Smith, MR; Urtishak, K; Wu, D | 1 |
| Beckstead, R; Cutshall, ZA; Dougherty, M; Haaland, B; Kohli, M; Kohli, R; Nelson, RE; Yoo, M | 1 |
| Curley, T; de Leeuw, R; Fernandez, C; Fleming, M; Gopalan, A; Halabi, S; Kang, P; Kelly, K; Knudsen, K; Luo, B; Molina, A; Shafi, A; Slovin, SF; Wolf, S | 1 |
| Adachi, T; Azuma, H; Fukuokaya, W; Hashimoto, T; Hirasawa, Y; Inamoto, T; Iwatani, K; Kimura, T; Komura, K; Maenosono, R; Mori, K; Nakamori, K; Nishimura, K; Ohno, T; Ohno, Y; Saruta, M; Shiroki, R; Takahara, K; Tokushige, S; Tsujino, T; Tsuzuki, S; Uchimoto, T; Urabe, F; Yamamoto, S; Yamazaki, S; Yanagisawa, T; Yoshizawa, A | 1 |
| Fallara, G; Malavaud, B; Martini, A; Ploussard, G | 1 |
26 review(s) available for prednisone and abiraterone acetate
| Article | Year |
|---|---|
Prostate cancer: The androgen receptor remains front and centre.
Topics: Abiraterone Acetate; Adenocarcinoma; Androgen Antagonists; Androgens; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Enzyme Inhibitors; Humans; Male; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Survival Rate; Taxoids | 2013 |
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
Topics: Abiraterone Acetate; Activities of Daily Living; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Australia; Canada; Cost of Illness; Disease Progression; Double-Blind Method; Drug Administration Schedule; Europe; Humans; Kaplan-Meier Estimate; Male; Pain; Pain Measurement; Prednisone; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Surveys and Questionnaires; Time Factors; Treatment Outcome; United States | 2013 |
Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstadienes; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Male; Multicenter Studies as Topic; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2013 |
[Abiraterone acetate (AA): current guidelines of prescription of abiraterone].
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplastic Cells, Circulating; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Taxoids | 2014 |
[Use of abiraterone acetate in the treatment of patients with metastatic castration resistant prostate cancer and no prior chemotherapy: 3 case reports and literature review].
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Humans; Male; Neoplasm Metastasis; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Retrospective Studies | 2014 |
Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.
Topics: Abiraterone Acetate; Androstadienes; Benzamides; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Practice Guidelines as Topic; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2014 |
[How to manage patients with CRPC?].
Topics: Abiraterone Acetate; Androstenes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Tissue Extracts | 2015 |
Interim Results From ERADICATE: An Open-Label Phase 2 Study of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Castration-Resistant Prostate Cancer Subjects With Symptomatic Bone Metastases.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemoradiotherapy; Clinical Trials, Phase II as Topic; Humans; Male; Prednisone; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Treatment Outcome | 2016 |
Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Humans; Male; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality-Adjusted Life Years; Technology Assessment, Biomedical; United Kingdom | 2017 |
The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide.
Topics: Abiraterone Acetate; Antineoplastic Agents; Benzamides; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Male; Nitriles; Phenylthiohydantoin; Polypharmacy; Prednisone; Prostatic Neoplasms | 2017 |
Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.
Topics: Abiraterone Acetate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant | 2017 |
Treatment of Castration-naive Metastatic Prostate Cancer.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2017 |
Second-line therapy in patients with metastatic castration-resistant prostate cancer with progression after or under docetaxel: A systematic review of nine randomized controlled trials.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic | 2017 |
Apalutamide: First Global Approval.
Topics: Abiraterone Acetate; Androgens; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Approval; Humans; Male; Prednisone; Prostatic Neoplasms; Receptors, Androgen; Thiohydantoins; United States; United States Food and Drug Administration | 2018 |
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Network Meta-Analysis; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2018 |
Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic | 2018 |
Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone.
Topics: Abiraterone Acetate; Androgen Antagonists; Drug Therapy, Combination; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase | 2019 |
A drug safety evaluation of abiraterone acetate in the treatment of prostate cancer.
Topics: Abiraterone Acetate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Quality of Life | 2019 |
Corticosteroid switch after progression on abiraterone acetate plus prednisone.
Topics: Abiraterone Acetate; Adrenal Cortex Hormones; Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Male; Middle Aged; Patient Selection; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2020 |
Pharmacotherapeutic strategies for castrate-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunotherapy; Male; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; Tissue Extracts | 2020 |
Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy.
Topics: Abiraterone Acetate; Androgen Antagonists; Animals; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Survival Rate | 2020 |
Optimal treatment sequencing of abiraterone acetate plus prednisone and enzalutamide in patients with castration-resistant metastatic prostate cancer: A systematic review and meta-analysis.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2021 |
Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer.
Topics: Abiraterone Acetate; Androgen Antagonists; Androgen Receptor Antagonists; Humans; Male; Prednisone; Prostatic Neoplasms; Receptors, Androgen | 2023 |
The safety of radium-223 combined with new-generation hormonal agents in bone metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Fractures, Bone; Humans; Male; Network Meta-Analysis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium | 2023 |
Association between RCT methodology and disease indication with mineralocorticoid-related toxicity for patients receiving abiraterone acetate for advanced prostate cancer: A meta-analysis of RCTs.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Humans; Hypertension; Hypokalemia; Male; Mineralocorticoids; Prednisone; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Treatment Outcome | 2023 |
Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective.
Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Bayes Theorem; Cost-Effectiveness Analysis; Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
78 trial(s) available for prednisone and abiraterone acetate
| Article | Year |
|---|---|
Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androgens; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Electrocardiography; Heart Rate; Humans; Long QT Syndrome; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prednisone; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase | 2012 |
Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Dextromethorphan; Drug Interactions; Follow-Up Studies; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Theophylline | 2013 |
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised tri
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Androstadienes; Bone Neoplasms; Double-Blind Method; Drug Therapy, Combination; Fractures, Spontaneous; Glucocorticoids; Humans; Male; Middle Aged; Pain Management; Pain Measurement; Palliative Care; Prednisone; Prostatic Neoplasms; Spinal Cord Compression; Steroid 17-alpha-Hydroxylase | 2012 |
Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Castration; Docetaxel; Fatigue; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Prednisone; Prostatic Neoplasms; Surveys and Questionnaires; Taxoids | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Double-Blind Method; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Survival Analysis | 2013 |
Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial.
Topics: Abiraterone Acetate; Androgens; Androstadienes; Double-Blind Method; Humans; Liquid-Liquid Extraction; Male; Orchiectomy; Prednisone; Prognosis; Prostatic Neoplasms; Testosterone | 2013 |
Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Agents; Cardiovascular Diseases; Comorbidity; Docetaxel; Follow-Up Studies; Humans; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2015 |
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
Topics: Abiraterone Acetate; Activities of Daily Living; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Australia; Canada; Cost of Illness; Disease Progression; Double-Blind Method; Drug Administration Schedule; Europe; Humans; Kaplan-Meier Estimate; Male; Pain; Pain Measurement; Prednisone; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Surveys and Questionnaires; Time Factors; Treatment Outcome; United States | 2013 |
Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Taxoids; Treatment Outcome; Viscera | 2014 |
Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
Topics: Abiraterone Acetate; Adult; Age Factors; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Double-Blind Method; Fatigue; Humans; Hypertension; Hypokalemia; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Survival Rate; Taxoids | 2014 |
Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Approval; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome; United States; United States Food and Drug Administration | 2013 |
Androgen dynamics and serum PSA in patients treated with abiraterone acetate.
Topics: Abiraterone Acetate; Androgens; Androstenes; Double-Blind Method; Humans; Kallikreins; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Testosterone; Treatment Outcome | 2014 |
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
Topics: Abiraterone Acetate; Aged; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cytochrome P-450 Enzyme Inhibitors; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Prednisone; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Steroid 17-alpha-Hydroxylase; Time Factors; Treatment Outcome | 2014 |
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Disease-Free Survival; Double-Blind Method; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Male; Middle Aged; Prednisone; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Trans-Activators; Transcriptional Regulator ERG | 2015 |
Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Disease-Free Survival; Double-Blind Method; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radiography; Survival Rate; Treatment Outcome | 2015 |
A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antigen-Presenting Cells; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphocyte Activation; Lymphocyte Count; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; T-Lymphocyte Subsets; Tissue Extracts; Treatment Outcome | 2015 |
Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Cytochrome P-450 Enzyme Inhibitors; Dietary Fats; Drug Therapy, Combination; Fasting; Female; Food-Drug Interactions; Healthy Volunteers; Humans; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2015 |
Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Glucocorticoids; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2015 |
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
Topics: Abiraterone Acetate; Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Double-Blind Method; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retreatment; Survival Rate; Taxoids | 2016 |
Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Double-Blind Method; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2016 |
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.
Topics: Abiraterone Acetate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Double-Blind Method; Humans; Male; Prednisone; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant | 2016 |
Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2016 |
Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study.
Topics: Abiraterone Acetate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; China; Disease-Free Survival; Docetaxel; Double-Blind Method; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2016 |
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Prednisone; Receptor, ErbB-2; Receptors, Androgen; Receptors, Progesterone; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Area Under Curve; Drug Therapy, Combination; Humans; L-Lactate Dehydrogenase; Male; Models, Biological; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Severity of Illness Index; Socioeconomic Factors; Testosterone | 2017 |
Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Antineoplastic Combined Chemotherapy Protocols; Black People; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant | 2016 |
Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction.
Topics: Abiraterone Acetate; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Humans; Kallikreins; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Time Factors; Treatment Outcome; United States | 2017 |
Testicular vs adrenal sources of hydroxy-androgens in prostate cancer.
Topics: Abiraterone Acetate; Adrenal Glands; Androgens; Antineoplastic Agents, Hormonal; Glucuronides; Humans; Leuprolide; Male; Neoadjuvant Therapy; Prednisone; Prostatic Neoplasms; Sulfates; Testis; Testosterone; Testosterone Congeners | 2017 |
Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
Topics: Abiraterone Acetate; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Europe; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2018 |
The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
Topics: Abiraterone Acetate; Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Humans; Male; Middle Aged; Neoplasm Grading; Pain; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Analysis | 2018 |
A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone.
Topics: Abiraterone Acetate; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Genome-Wide Association Study; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Wnt Signaling Pathway | 2018 |
Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Gastrointestinal Diseases; Humans; Male; Methylprednisolone; Middle Aged; Neoplasm Metastasis; Particle Size; Prednisone; Prostatic Neoplasms, Castration-Resistant; Therapeutic Equivalency | 2018 |
eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Treatment Outcome | 2018 |
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Topics: Abiraterone Acetate; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Internationality; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Patient Reported Outcome Measures; Prednisone; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Risk Assessment; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Humans; Kallikreins; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Prednisone; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2018 |
Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Double-Blind Method; Endpoint Determination; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Placebos; Prednisone; Progression-Free Survival; Prostatic Neoplasms; Treatment Outcome | 2018 |
Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: Results from LATITUDE.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Follow-Up Studies; Health Resources; Hospitalization; Humans; Male; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Rate | 2019 |
Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.
Topics: Abiraterone Acetate; Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Drug Administration Schedule; Follow-Up Studies; Humans; Lymphatic Irradiation; Male; Middle Aged; Neoplasm Staging; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies | 2019 |
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Abiraterone Acetate; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Double-Blind Method; Fractures, Bone; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Humans; Leuprolide; Male; Middle Aged; Neoplasm Micrometastasis; Prednisone; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiosurgery; Thiohydantoins; Treatment Outcome; Veterans; Young Adult | 2019 |
Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Double-Blind Method; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2019 |
The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels.
Topics: Abiraterone Acetate; Adenocarcinoma; Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Goserelin; Humans; Male; Patient Reported Outcome Measures; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Testosterone; Thiohydantoins; Treatment Outcome | 2019 |
Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Drug Combinations; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Prednisone; Preoperative Period; Prostatectomy; Prostatic Neoplasms; Risk Assessment | 2019 |
Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study.
Topics: Abiraterone Acetate; Antineoplastic Agents; Double-Blind Method; Humans; Leukocyte Count; Lymphocytes; Male; Neutrophils; Predictive Value of Tests; Prednisone; Prostatic Neoplasms; Retrospective Studies; Treatment Outcome | 2020 |
Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT).
Topics: Abiraterone Acetate; Affect; Aged; Aged, 80 and over; Amnesia; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Caregivers; Cognitive Dysfunction; Confusion; Fatigue; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2019 |
Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Male; Neoplasm Metastasis; Nitriles; Patient Reported Outcome Measures; Phenylthiohydantoin; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Time Factors | 2020 |
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cross-Over Studies; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Rate | 2019 |
Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia; Canada; Double-Blind Method; Drug Substitution; Europe; Humans; International Agencies; Latin America; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Treatment Outcome | 2019 |
A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bone Neoplasms; Disease-Free Survival; Double-Blind Method; Fractures, Bone; Humans; Male; Middle Aged; Placebos; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium; Treatment Outcome | 2020 |
Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivatio
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents; Correlation of Data; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Prednisone; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate | 2020 |
Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Survival Analysis | 2020 |
Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Humans; Kallikreins; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Thiohydantoins; Treatment Outcome | 2020 |
A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Random Allocation; Sunitinib; Treatment Outcome; Tumor Microenvironment | 2021 |
Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Prednisone; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant | 2020 |
Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Confidence Intervals; Drug Therapy, Combination; Humans; Male; Middle Aged; Prednisone; Progression-Free Survival; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Seminal Vesicles; Testosterone; Time Factors | 2021 |
Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Drug Therapy, Combination; Humans; Leuprolide; Male; Middle Aged; Prednisone; Preoperative Period; Prostatectomy; Prostatic Neoplasms; Risk Assessment; Thiohydantoins; Treatment Outcome | 2021 |
A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium; Tomography, X-Ray Computed | 2021 |
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
Topics: Abiraterone Acetate; Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2021 |
Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Follow-Up Studies; Humans; Kallikreins; Male; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Time Factors | 2021 |
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
Topics: Abiraterone Acetate; Aged; Androgen Receptor Antagonists; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Neoplasm Metastasis; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Steroid Synthesis Inhibitors; Survival Rate; Thiohydantoins | 2021 |
Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Castration; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms, Second Primary; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2022 |
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors.
Topics: Abiraterone Acetate; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Chromones; Humans; Lung Neoplasms; Male; Neoplasms; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms | 2022 |
Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.
Topics: Abiraterone Acetate; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2022 |
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Topics: Abiraterone Acetate; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Hormones; Humans; Male; Prednisolone; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2022 |
LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Gonadotropin-Releasing Hormone; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Testosterone; Treatment Outcome | 2022 |
Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Castration; Disease-Free Survival; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metformin; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2022 |
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.
Topics: Abiraterone Acetate; Acetates; Androgen Antagonists; Cost-Benefit Analysis; Hormones; Humans; Male; Prednisolone; Prednisone; Prostatic Neoplasms; State Medicine | 2022 |
Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: A randomised clinical trial (HEAT).
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Diabetes Mellitus, Type 2; Fatigue; Glycated Hemoglobin; Hot Temperature; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Treatment Outcome | 2022 |
Comments on "Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)".
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Hormones; Humans; Male; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2022 |
Clinical Outcomes of First Subsequent Therapies After Abiraterone Acetate Plus Prednisone for High-Risk Metastatic Castration-Sensitive Prostate Cancer in the LATITUDE Study.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Castration; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2023 |
A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Humans; Male; Phosphatidylinositol 3-Kinases; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2023 |
Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Exanthema; Humans; Hyperglycemia; Male; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2023 |
Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Receptors, Androgen; Treatment Outcome | 2023 |
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2023 |
Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Nitriles; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Recombinational DNA Repair; Treatment Outcome | 2023 |
Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2023 |
100 other study(ies) available for prednisone and abiraterone acetate
| Article | Year |
|---|---|
Drug helps slow advanced prostate cancer.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Humans; Male; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Abiraterone acetate: a hat trick of clinical benefits.
Topics: Abiraterone Acetate; Androgen Antagonists; Androstadienes; Bone Neoplasms; Glucocorticoids; Humans; Male; Pain Management; Prednisone; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase | 2012 |
Biochemical and objective response to abiraterone acetate withdrawal: incidence and clinical relevance of a new scenario for castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Androgen Antagonists; Androstadienes; Disease Progression; Docetaxel; Follow-Up Studies; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2013 |
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androgen Antagonists; Androstadienes; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Humans; Kallikreins; L-Lactate Dehydrogenase; Lymphocytes; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neutrophils; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Steroid 17-alpha-Hydroxylase; Treatment Outcome | 2014 |
Adherence patterns for abiraterone acetate and concomitant prednisone use in patients with prostate cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androgen Antagonists; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Drug Prescriptions; Drug Utilization Review; Health Knowledge, Attitudes, Practice; Humans; Insurance, Pharmaceutical Services; Male; Managed Care Programs; Medicare; Medication Adherence; Middle Aged; Practice Patterns, Physicians'; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Time Factors; Treatment Outcome; United States | 2014 |
Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiography; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of ≥ 85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Humans; Male; Neoplasm Staging; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2015 |
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Odds Ratio; Prednisone; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Steroid Synthesis Inhibitors; Time Factors; Treatment Outcome | 2015 |
Risks, benefits, and approaches to hormonal blockade in prostate cancer. Highlights from the European Association of Urology Meeting, March 20-24, 2015, Madrid, Spain.
Topics: Abiraterone Acetate; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cognition; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Luteinizing Hormone; Male; Mice; Mortality; Myocardial Infarction; Oligopeptides; Prednisone; Prostatic Neoplasms; Risk Assessment; Stroke | 2015 |
Ureteral Metastasis: Uncommon Manifestation in Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Ureteral Neoplasms | 2015 |
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Hyperglycemia; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Time Factors; Weight Gain | 2016 |
Prednisone Use in Conjunction with Abiraterone Acetate: Is Patient Safety a Concern with Long-term Steroid Exposure?
Topics: Abiraterone Acetate; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Humans; Patient Safety; Prednisone; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase | 2016 |
Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Costs and Cost Analysis; Disease Progression; Disease-Free Survival; Drug Therapy, Combination; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2016 |
Re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Adrenal Cortex Hormones; Aged; Humans; Incidence; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2016 |
Reply to Giandomenico Roviello, Alberto Bottini, and Daniele Generali's Letter to the Editor re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Giv
Topics: Abiraterone Acetate; Adrenal Cortex Hormones; Aged; Humans; Incidence; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2016 |
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Topics: Abiraterone Acetate; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Practice Patterns, Physicians'; Prednisone; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids | 2017 |
Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Alleles; Antineoplastic Agents; Disease Progression; Genotype; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Odds Ratio; Polymorphism, Single Nucleotide; Prednisone; Proportional Hazards Models; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Treatment Outcome | 2016 |
Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http
Topics: Abiraterone Acetate; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2017 |
Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Disease-Free Survival; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2017 |
Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http
Topics: Abiraterone Acetate; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2017 |
Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Androgens; Animals; Biopsy; Cell Line, Tumor; Dehydroepiandrosterone; Humans; Hydrocortisone; Male; Mass Spectrometry; Mice; Mice, SCID; Naphthalenes; Neoplasm Transplantation; Precision Medicine; Prednisone; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction; Steroid 17-alpha-Hydroxylase; Triazoles | 2016 |
Reply to Robert J. van Soest and Ronald de Wit's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Pros
Topics: Abiraterone Acetate; Humans; Male; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 2017 |
Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone.
Topics: Abiraterone Acetate; Aged; Antineoplastic Combined Chemotherapy Protocols; Eplerenone; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Spironolactone; Survival Analysis; Treatment Outcome | 2017 |
Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?
Topics: Abiraterone Acetate; Aged; Docetaxel; Humans; Male; Prednisone; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; ROC Curve; Survival Analysis; Taxoids; Treatment Outcome | 2017 |
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Topics: Abiraterone Acetate; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Signal Transduction; Steroid Synthesis Inhibitors; Time Factors; Treatment Outcome | 2017 |
Comment on: "Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal".
Topics: Abiraterone Acetate; Disease-Free Survival; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2017 |
Response to Letter to the Editor Regarding "Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal".
Topics: Abiraterone Acetate; Disease-Free Survival; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2017 |
Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate.
Topics: Abiraterone Acetate; Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Castration; Disease-Free Survival; Humans; Male; Neoplasm Metastasis; Prednisolone; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Antitumor Activity and Safety of Enzalutamide After Abiraterone Acetate: Seeking the Optimal Treatment Sequence for Castration-resistant Prostate Cancer Patients.
Topics: Abiraterone Acetate; Benzamides; Europe; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2018 |
Customizing Daily Management of Castrate-resistant Prostate Cancer: Waiting for the Next Step.
Topics: Abiraterone Acetate; Humans; Male; Neoplasm Grading; Pain; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2018 |
Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-301 and COU-AA-302.
Topics: Abiraterone Acetate; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Surveys and Questionnaires; Treatment Outcome | 2018 |
Prostate cancers that 'Wnt' respond to abiraterone.
Topics: Abiraterone Acetate; Androstenes; Cell Cycle; Cell Proliferation; Genome-Wide Association Study; Humans; Male; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Wnt Signaling Pathway | 2018 |
Considering quantity and quality of life in metastatic castration-naive prostate cancer.
Topics: Abiraterone Acetate; Humans; Male; Patient Reported Outcome Measures; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life | 2018 |
Prostate cancer: PROMs suggest a festival of benefits in LATITUDE.
Topics: Abiraterone Acetate; Androgen Antagonists; Holidays; Humans; Male; Patient Reported Outcome Measures; Prednisone; Prostatic Neoplasms | 2018 |
Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Anti-Inflammatory Agents; Docetaxel; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
EMA guidance on radium-223 dichloride in prostate cancer.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; European Union; Fractures, Bone; Humans; Male; Prednisone; Prostatic Neoplasms; Radioisotopes; Radium; Survival Rate | 2018 |
Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Antineoplastic Combined Chemotherapy Protocols; Germ-Line Mutation; Humans; Male; Middle Aged; Multienzyme Complexes; Pharmacogenomic Variants; Point Mutation; Precision Medicine; Prednisone; Progesterone Reductase; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Steroid Isomerases | 2018 |
Long-term abiraterone withdrawal syndrome.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Substance Withdrawal Syndrome; Treatment Outcome | 2018 |
Editorial Comment.
Topics: Abiraterone Acetate; Disease Progression; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2018 |
Editorial Comment.
Topics: Abiraterone Acetate; Disease Progression; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2018 |
Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Time Factors; Treatment Failure; Treatment Outcome | 2018 |
Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC).
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Glucocorticoids; Humans; Male; Pilot Projects; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2018 |
Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone.
Topics: Abiraterone Acetate; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2018 |
Fatigue, treatment satisfaction and health-related quality of life among patients receiving novel drugs suppressing androgen signalling for the treatment of metastatic castrate-resistant prostate cancer.
Topics: Abiraterone Acetate; Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Fatigue; Health Status; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Patient Satisfaction; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Qualitative Research; Quality of Life | 2019 |
Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Humans; Male; Middle Aged; Prednisone; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2018 |
Germline Variant in
Topics: Abiraterone Acetate; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease-Free Survival; Genotype; Germ-Line Mutation; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Organic Anion Transporters; Polymorphism, Single Nucleotide; Prednisone; Prostate; Prostatic Neoplasms, Castration-Resistant | 2019 |
Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Antigens, Differentiation; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Monitoring; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Patient Selection; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant | 2019 |
Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prednisone; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2019 |
Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Fractures, Bone; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium; Treatment Outcome | 2019 |
Combination therapies in prostate cancer: proceed with caution.
Topics: Abiraterone Acetate; Double-Blind Method; Humans; Male; Prednisolone; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
LC-MS/MS assay for the quantification of testosterone, dihydrotestosterone, androstenedione, cortisol and prednisone in plasma from castrated prostate cancer patients treated with abiraterone acetate or enzalutamide.
Topics: Abiraterone Acetate; Androstenedione; Benzamides; Chromatography, Liquid; Dihydrotestosterone; Humans; Hydrocortisone; Male; Nitriles; Phenylthiohydantoin; Plasma; Prednisone; Prostatic Neoplasms, Castration-Resistant; Tandem Mass Spectrometry; Testosterone | 2019 |
Importance of early treatment in metastatic prostate cancer: a question of life or death.
Topics: Abiraterone Acetate; Castration; Double-Blind Method; Humans; Male; Prednisone; Prostatic Neoplasms; Survival Analysis | 2019 |
Early use of abiraterone and radium-223 in metastatic prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Double-Blind Method; Humans; Male; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
Early use of abiraterone and radium-223 in metastatic prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Double-Blind Method; Humans; Male; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Fasting; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant | 2019 |
Re: Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in Patients with Castration-resistant Prostate Cancer and Bone Metastases (ERA 223): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial.
Topics: Abiraterone Acetate; Bone Neoplasms; Double-Blind Method; Humans; Male; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).
Topics: Abiraterone Acetate; Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Docetaxel; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Male; Middle Aged; Multivariate Analysis; Pain; Prednisone; Progression-Free Survival; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Spain; Taxoids; Treatment Outcome | 2019 |
Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.
Topics: Abiraterone Acetate; Absorptiometry, Photon; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2019 |
Considering bone health in the treatment of prostate cancer bone metastasis based on the results of the ERA-223 trial.
Topics: Abiraterone Acetate; Bone Density; Bone Neoplasms; Double-Blind Method; Humans; Male; Prednisolone; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
Combination treatment in metastatic castration-resistant prostate cancer: can we safely boost efficacy by adding radium-223?
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Humans; Male; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium | 2020 |
Real-world outcome with abiraterone acetate plus prednisone in Asian men with metastatic castrate-resistant prostate cancer: The Singapore experience.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Drug Therapy, Combination; Humans; Male; Middle Aged; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Singapore; Survival Rate | 2020 |
Sequence of AR inhibitors affects outcome.
Topics: Abiraterone Acetate; Benzamides; Cross-Over Studies; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2020 |
Androgen receptor-targeted agents in the management of advanced prostate cancer.
Topics: Abiraterone Acetate; Benzamides; Cross-Over Studies; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2019 |
Abiraterone acetate treatment lowers 11-oxygenated androgens.
Topics: Abiraterone Acetate; Adrenal Hyperplasia, Congenital; Adult; Androgens; Androstenes; Chromatography, Liquid; Cytochrome P-450 Enzyme Inhibitors; Drug Therapy, Combination; Humans; Male; Prednisone; Prostatic Neoplasms; Tandem Mass Spectrometry; Testosterone | 2020 |
Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Topics: Abiraterone Acetate; Adult; Aged; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Cohort Studies; Drug Administration Schedule; Health Care Costs; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2020 |
Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome.
Topics: Abiraterone Acetate; Administration, Oral; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Bone Neoplasms; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Incidence; Liver Function Tests; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Remission, Spontaneous | 2020 |
Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Adult; Aged; Anti-Inflammatory Agents; Biomarkers, Tumor; Cell-Free Nucleic Acids; DNA Copy Number Variations; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Steroid Synthesis Inhibitors; Survival Rate; Treatment Outcome | 2020 |
[Early- vs. late-onset treatment using abiraterone acetate plus prednisone in chemo-naïve, asymptomatic or mildly symptomatic patients with metastatic CRPC after androgen deprivation therapy].
Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Humans; Male; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2020 |
Re: Nobuaki Matsubara, Kim N. Chi, Mustafa Özgüroğlu, et al. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Ace
Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Castration; Humans; Kinetics; Male; Prednisone; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2020 |
Predictors of resistance to abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer in post-docetaxel setting: a single-center cohort study.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2020 |
[Sequential therapy for asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer].
Topics: Abiraterone Acetate; Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2020 |
Clinical Experience of Steroid Switch from Prednisone to Dexamethasone in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate.
Topics: Abiraterone Acetate; Antineoplastic Agents; Dexamethasone; Drug Substitution; Glucocorticoids; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2021 |
Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome; Veterans | 2021 |
Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment.
Topics: Abiraterone Acetate; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Case-Control Studies; Disease-Free Survival; Female; Humans; Kallikreins; Liquid Biopsy; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; RNA, Messenger; Treatment Outcome | 2021 |
Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry.
Topics: Abiraterone Acetate; Aged; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Registries | 2021 |
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Male; Prednisone; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2021 |
Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer.
Topics: Abiraterone Acetate; Cost-Benefit Analysis; Docetaxel; Hormones; Humans; Male; Markov Chains; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Therapies, Investigational; Treatment Outcome | 2021 |
Should Patients with High-risk Localised or Locally Advanced Prostate Cancer Receive Abiraterone Acetate in Addition to Androgen Deprivation Therapy? Update on a Planned Analysis of the STAMPEDE Trial.
Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2021 |
Treatment of Metastatic Castration-resistant Prostate Cancer Patients With Abiraterone Acetate and Prednisone and Corresponding Survival Prognostic Factors.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Agents; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant | 2021 |
Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Cohort Studies; Humans; Kaplan-Meier Estimate; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Registries; Retrospective Studies | 2021 |
Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexamethasone; Disease Progression; Drug Substitution; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prednisone; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2021 |
The effect of chemotherapy on the exposure-response relation of abiraterone in metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2022 |
Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Benzamides; Bone Neoplasms; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies | 2022 |
Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Belgium; Data Analysis; Docetaxel; Hormones; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Treatment Outcome | 2022 |
Prostate Cancer Metastasis to the Pituitary Gland Manifesting as Corticosteroid Withdrawal, and the Impact of the Switch from Prednisone to Dexamethasone on Survival Time.
Topics: Abiraterone Acetate; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Male; Pituitary Gland; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2021 |
Synthesis and characterization of epoxide impurities of abiraterone acetate.
Topics: Abiraterone Acetate; Androgen Antagonists; Epoxy Compounds; Humans; Male; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 2022 |
Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study.
Topics: Abiraterone Acetate; Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Pain; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Retrospective Studies | 2022 |
Ascending Flaccid Paralysis Secondary to Hypokalemia in A Cancer Patient using Abiraterone - A Case Report.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Hypokalemia; Male; Paralysis; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2023 |
Should LHRH therapy be continued in patients receiving abiraterone acetate?
Topics: Abiraterone Acetate; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Gonadotropin-Releasing Hormone; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2022 |
Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2022 |
Does Clinical Evidence of Heterogeneity Impact Treatment Selection? A Case Study of Abiraterone for Metastatic Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Prednisone; Prostatic Neoplasms | 2022 |
Enzalutamide or Abiraterone Acetate With Prednisone in the Treatment of Metastatic Castration-resistant Prostate Cancer in Real-life Clinical Practice: A Long-term Single Institution Experience.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Nitriles; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Nitriles; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Castration; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
Re: Niraparib and Abiraterone Acetate for Metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Indazoles; Male; Piperidines; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2023 |
[New drug approval: Fixed dose association of niraparib and abiraterone acetate in metastatic castration resistant prostate cancer with BRCA1/2 mutation].
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Drug Approval; Humans; Male; Mutation; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2023 |
Abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer: a real-world retrospective study in China.
Topics: Abiraterone Acetate; Adolescent; Adult; Humans; Hypertension; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2023 |
Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
Combination therapy with olaparib and abiraterone acetate for metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Phthalazines; Piperazines; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2023 |